Paul Nestel1, Akihiko Fujii, Lei Zhang. 1. Baker Heart Research Institute Wynm Domain, Melbourne, Australia. paul.nestel@baker.edu.au <paul.nestel@baker.edu.au>
Abstract
OBJECTIVES:Isoflavones reduce arterial stiffness, a predictor of cardiovascular events. Whether metabolites of isoflavones have similar bioactivity is unknown. The effect of supplemental trans-tetrahydrodaidzein (THD) a metabolite of daidzein on pulse wave velocity (PWV), a measure of arterial stiffness was tested in overweight men and postmenopausal women. METHODS:25 subjects, 11 postmenopausal women, 14 men (age, 57 [7] years; body mass index, 30.3 [4.7]kg/m(2); mean [S.D.]) participated in a double-blind, randomized, cross-over trial of THD versus placebo. DESIGN: 2 weeks run-in followed by either THD 1g daily or placebo, each intervention 5 weeks. Aorta-femoral artery PWV, blood pressure and plasma lipids were measured after run-in, THD and placebo. RESULTS:PWV was significantly reduced (signifying diminished central arterial stiffness): medians (25th and 75th%), placebo 9.9 m/s (8.7, 11.1), THD 8.8m/s (7.9, 10.9); RM ANOVA P=0.023, with Tukey procedure P<0.05. Systolic blood pressure was significantly reduced: means (S.D.), placebo 125.6 (14.7), THD 121.3 (12.2)mmHg; Tukey P<0.05. Plasma cholesterol, triglyceride and LDL cholesterol did not differ significantly. Absorption of THD >80% substantially exceeded that of parent isoflavones. CONCLUSION: A metabolite normally formed after consumption of isoflavones (formononetin, daidezein), taken orally, reduced blood pressure and central arterial stiffness indicating reduced cardiovascular risk.
RCT Entities:
OBJECTIVES:Isoflavones reduce arterial stiffness, a predictor of cardiovascular events. Whether metabolites of isoflavones have similar bioactivity is unknown. The effect of supplemental trans-tetrahydrodaidzein (THD) a metabolite of daidzein on pulse wave velocity (PWV), a measure of arterial stiffness was tested in overweight men and postmenopausal women. METHODS: 25 subjects, 11 postmenopausal women, 14 men (age, 57 [7] years; body mass index, 30.3 [4.7]kg/m(2); mean [S.D.]) participated in a double-blind, randomized, cross-over trial of THD versus placebo. DESIGN: 2 weeks run-in followed by either THD 1g daily or placebo, each intervention 5 weeks. Aorta-femoral artery PWV, blood pressure and plasma lipids were measured after run-in, THD and placebo. RESULTS: PWV was significantly reduced (signifying diminished central arterial stiffness): medians (25th and 75th%), placebo 9.9 m/s (8.7, 11.1), THD 8.8m/s (7.9, 10.9); RM ANOVA P=0.023, with Tukey procedure P<0.05. Systolic blood pressure was significantly reduced: means (S.D.), placebo 125.6 (14.7), THD 121.3 (12.2)mmHg; Tukey P<0.05. Plasma cholesterol, triglyceride and LDL cholesterol did not differ significantly. Absorption of THD >80% substantially exceeded that of parent isoflavones. CONCLUSION: A metabolite normally formed after consumption of isoflavones (formononetin, daidezein), taken orally, reduced blood pressure and central arterial stiffness indicating reduced cardiovascular risk.
Authors: P B Clifton-Bligh; M-L Nery; R J Clifton-Bligh; S Visvalingam; G R Fulcher; K Byth; R Baber Journal: Eur J Clin Nutr Date: 2014-11-05 Impact factor: 4.016
Authors: Julie A Mattison; George S Roth; T Mark Beasley; Edward M Tilmont; April M Handy; Richard L Herbert; Dan L Longo; David B Allison; Jennifer E Young; Mark Bryant; Dennis Barnard; Walter F Ward; Wenbo Qi; Donald K Ingram; Rafael de Cabo Journal: Nature Date: 2012-09-13 Impact factor: 49.962
Authors: Chesney K Richter; Ann C Skulas-Ray; Jennifer A Fleming; Christina J Link; Ratna Mukherjea; Elaine S Krul; Penny M Kris-Etherton Journal: Br J Nutr Date: 2017-05 Impact factor: 3.718